EMV has seen continued absorption of shares following its recent rerate. With such a tight register and significant demand, coinciding with the resumption of the clinical trial, MRFF Stage 2 fund grant bids nearing completion (potential massive grant up for grabs that EMV has already successfully obtained stage 1) EMV is well poised to continue its upward trend.
The chart is showing a bullish flag continuation pattern with an approximate target of $1.90.